NCT02598999View on ClinicalTrials.gov

Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Cystic FibrosisBronchiectasis
Interventions
DRUG

ALX-009

Solution for inhalation administered through nebulization

DRUG

OSCN-

Solution for inhalation administered through nebulization

DRUG

bLF

Solution for inhalation administered through nebulization

DRUG

Placebo

Solution for inhalation administered through nebulization, Sodium Chloride 0.9%

Trial Locations (1)

Unknown

Eurofins Optimed, Grenoble

Sponsors

Lead Sponsor

Alaxia SAS
All Listed Sponsors
lead

Alaxia SAS

INDUSTRY

NCT02598999 - Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients | Biotech Hunter | Biotech Hunter